N-(4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-chlorophenethyl)-7-amino-3-methylthieno[3,2-b]pyrazine-6-carboxamide hydrochloride

ID: ALA4173102

Chembl Id: CHEMBL4173102

PubChem CID: 141734631

Max Phase: Preclinical

Molecular Formula: C22H26Cl2N6OS

Molecular Weight: 457.00

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cnc2c(N)c(C(=O)NCCc3ccc(N4CC5CCC(C4)N5)c(Cl)c3)sc2n1.Cl

Standard InChI:  InChI=1S/C22H25ClN6OS.ClH/c1-12-9-26-19-18(24)20(31-22(19)27-12)21(30)25-7-6-13-2-5-17(16(23)8-13)29-10-14-3-4-15(11-29)28-14;/h2,5,8-9,14-15,28H,3-4,6-7,10-11,24H2,1H3,(H,25,30);1H

Standard InChI Key:  NRKCZHCBKJKAFT-UHFFFAOYSA-N

Associated Targets(Human)

USP25 Tchem Ubiquitin carboxyl-terminal hydrolase 25 (268 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
USP28 Tchem Ubiquitin carboxyl-terminal hydrolase 28 (268 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 457.00Molecular Weight (Monoisotopic): 456.1499AlogP: 3.15#Rotatable Bonds: 5
Polar Surface Area: 96.17Molecular Species: BASEHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 9.83CX LogP: 3.04CX LogD: 0.67
Aromatic Rings: 3Heavy Atoms: 31QED Weighted: 0.55Np Likeness Score: -1.31

References

1. Kargbo RB..  (2017)  Ubiquitin-Specific Inhibitors for the Treatment of Cancers, Autoimmune, and Infectious Diseases.,  (12): [PMID:29259735] [10.1021/acsmedchemlett.7b00449]
2.  (2017)  Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors,